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Abstract: In Portugal, in 2012, 73 children <15 years and 32 children <5 years 
developed Tuberculosis (TB). The aim of this study was to characterize TB in 
Portuguese children: diagnostic, clinical manifestations and factors associated with 
severe forms of disease. We analysed all children <6 years with TB between 
January/2003 and December/2012 - mandatory. Parameters in subjects with mild/severe 
TB were compared using Pearson’s chi-square tests and gross effects analysis. 364 
children were studied, mean age of 2.5±2.0 years. 330 (91%) were born in Portugal of 
which 161 (44.4%) in Lisbon/Oporto. 351 (96%) didn’t have any comorbidity and 204 
(56%) had known BCG vaccination. Median time from symptom onset until diagnosis 
was 83 days. TB was more frequently detected by passive (n=216, 59%) than by active 
(n=128, 35%) screening. 236 (65%) had pulmonary manifestations and in chest 
radiography, performed in 346 children, 171 (72.5%) presented non-cavitary forms. 311 
(85.4%) presented mild TB and 53 (14.6%) severe TB. No predictors of severe 
manifestations were identified. 26% of the children had diagnostic confirmation (culture 
positive). TB among children is still a problem in our country particularly in the two 
large urban centres. We didn’t identify predictors of severe forms of disease. 
 
Introduction 
An estimated 9 million individuals worldwide develop tuberculosis (TB) 
annually, including 1 million children under age 15 years. [1] In 2012, 2,599 individuals 
in Portugal were diagnosed with TB, including 73 children under age 15 years and 32 
children under age 5 years. [2]  
Children infected with Mycobacterium tuberculosis have a higher likelihood 
than adults of progression to active disease, [1, 3] with this likelihood being even higher 
in children under age of 5 years. The risks for progression to active disease have been 
reported to be 50% in children under 1 year old, 10-20% in children aged between 1 and 
2 years and 5% in children aged between 2 and 5 years. [4] Most of these individuals 
experience disease progression during the first year after infection. Moreover, the 
immune system in children is not fully developed. Taken together, these findings 
indicate recent transmission of Mycobacterium tuberculosis in the population.
  
[3] 
Furthermore, children under age 2 years and those who are immunocompromised are 
susceptible to more severe and potentially fatal forms of TB. [5] 
Diagnostic confirmation by identification of the infectious agent is a 
complicated process in children. Obtaining samples is difficult, and, even if obtained, 
the paucibacillary nature of lesions can yield false negative laboratory results. [3] It is 
even more difficult in patients with extra-pulmonary disease, more prevalent in children 
than in adults. [3] In Europe between 2000 and 2009, only 42.3% of paediatric patients 
with TB underwent culture analysis, with these results being positive in 39.9%. [1] 
Culture confirmation rates were found to be 19.2% in Europe during 2009 [1] and 
27.6% in Portugal from 2000 to 2009.
 
[6] Currently, appropriate clinical presentation, 
history of recent contact with infected individuals, immunological evidence of infection 
and radiological signs compatible with TB are considered indicators of TB and suggest 
that treatment of TB should be started.
 
[3, 7, 8] However, the variability and low 
specificity of clinical and radiological findings in children indicate a need for a high 
level of suspicion. [3] 
Thus, better methods of diagnosis can result in better disease control in 
individual patients, as well as providing more valid statistics, advances in clinical 
research and a better integration of TB into national disease control programs.
 
[9] 
This study was therefore designed to characterize TB in Portuguese children by 
diagnostic assessment and clinical manifestations of the disease, as well as to 
characterize the factors associated with more severe forms of TB. 
 
Methods 
In Portugal, all individuals with TB are diagnosed and treated for free under the 
National Health System, with affected individuals referred to tuberculosis outpatient 
centres (CDPs) in their areas of residence. These centres are responsible for the 
diagnosis and treatment of non-hospitalized individuals with TB, as well as for the 
screening of high-risk populations. All patients diagnosed with TB are reported to the 
National Tuberculosis Surveillance System (SVIG-TB).  
In this study we included all children under 6 years old who were diagnosed 
with TB and reported to the SVIG-TB between January 1, 2003, and December 31, 
2012. Variables analysed included age, country of origin, method of disease detection, 
time from symptom onset to diagnosis, immunosuppressive comorbidities, 
administration of bacillus Calmette-Guérin (BCG) vaccine, tuberculin test (TST) 
results, interferon gamma assay (IGRA) results, clinical presentation, and confirmation 
by microscopy and/or bacterial culture. Subjects with invalid or missing data were 
excluded.   
Forms of TB considered mild included lymphatic extrathoracic or intrathoracic, 
pleural, pulmonary or pleuro-pulmonary. All other forms were defined as severe, 
including the involvement of more than one organ and genitourinary, meningeal, central 
nervous system (SNC) non-meningeal, osteoarticular non-vertebral, and vertebral and 
digestive/peritoneal tuberculosis.  
Parameters in subjects with mild and severe tuberculosis were compared using 
Pearson’s chi-square tests for categorical variables and gross effects analysis for 
continuous variables. Analysis of the database did not require approval by the Ethics 
Committee, due to the retrospective nature of the study and the impossibility of linking 
patients’ records to personal data. 
 
Results 
Survey of the SVIG-TB database identified 364 children under 6 years old, 165 
(45%) females and 199 (55%) males, who were diagnosed with TB between January 1, 
2003, and December 31, 2012. Mean patient age was approximately 2.5 (SD 2.0 years), 
and 330 (91%) were born in Portugal, of which 161 (44.4%) in the cities of Lisbon and 
Oporto. Of the 364 children, 351 (96%) did not have any associated comorbidity, 
including diabetes or infection with human immunodeficiency virus (HIV). Only 7 
children (1.9%) were HIV infected at diagnosis. We found that 204 of these children 
(56%) had been vaccinated for BCG and 26 (7%) had not been vaccinated. No 
information about vaccination was available for the remaining 134 (37%) patients. The 
median time from symptom onset until diagnosis of TB was 83 days. TB was more 
frequently detected by passive (n = 216, 59%) than by active (n = 128, 35%) screening; 
of the latter, 126 (98%) were screened after contact with a patient with TB. The 
remaining 20 (5.5%) children had no information about screening. 
Of the total 364 patients, 236 (65%) had pulmonary manifestations of TB; of the 
latter, 41 (17%) had extra-pulmonary manifestations and 194 (82%) did not. Among all 
children, 169 (46%) presented with extra-pulmonary forms of TB, including 49 (13.5%) 
with disseminated, 36 (9.9%) with lymphatic intrathoracic, and 33 (9%) with lymphatic 
extrathoracic forms. In addition 11 (3%) had pleural forms, four (1%) presented with 
CNS meningeal and two (0.5%) with non-meningeal forms, five (1.4%) with 
osteoarthritic vertebral, nine (2.5%) with osteoarthritic non-vertebral, three (0.8%) with 
genito-urinary, and one (0.3%) with digestive/peritoneal forms of TB. Thirteen patients 
(3.6%) had other forms of TB and four (1.1%) had unknown types. 
Of the 364 children, 311 (85.4%) presented mild TB and the other 53 (14.6%) 
severe TB. No predictors of severe manifestations of disease could be identified, 
including immunosuppressive comorbidities, BCG inoculation, residence or time to 
diagnosis (Table 1).  
Chest radiography was performed in 346 children (95%). Of the 236 children 
with pulmonary involvement, 171 (72.5%) presented with non-cavitary forms, 31 (13%)  
with cavitary forms, and 19 (8%) with no change. Results could not be determined for 
the other 15 (6.4%) patients. 
The TST was performed in 279 children (76.6%) and the IGRA in 10 (3%). 
In evaluating methods of diagnostic confirmation, we found that 172 children 
(47%) were not evaluated by microbacteriological methods, whether direct or cultural. 
Of the 192 subjects evaluated by direct methods, 69 (36%) had positive outcomes, 
whereas, of the 158 subjects assessed by culture, 94 (59%) had positive outcomes. Of 
all children, 124 (34%) had probable or confirmed diagnoses (positive on direct assays 
or on bacterial culture) and 26% had diagnostic confirmation (positive culture results). 
Of those assessed microbacteriologically, 122 (63.5%) had probable or confirmed 
diagnoses. Species were identified in 20% of these children.  
  
Discussion 
The mean age of the 364 Portuguese children with TB was approximately 2.5 
years, similar to studies in other countries, including a recent Mexican study with a 
similar average age (3 years). [10] However, the last Europe-wide study showed that, in 
Portugal, only 42.9% of children <14 years with TB were aged 0-4 years. [11] Most of 
the children with TB were born in Portugal, and almost 50% resided in Lisbon and 
Oporto, the two largest urban centres in the country and the areas of highest incidence 
of TB in Portugal. [2] 
Immunosuppression is an important risk factor for TB. HIV infection affects 
both the epidemiology and severity of TB, increasing the risk of developing and 
disseminating TB. [12] Nevertheless, 96% of the children surveyed had no associated 
immunosuppressive comorbidity, with only about 2% being HIV positive. In 
comparison, HIV/TB rates were reported to be 8% in Mexico and 1.5% in Peru, [13] but 
12% to 37% in developing countries. [14] 
  
The role of BCG vaccination in protecting against TB remains unclear.[10] BCG 
has been shown to protect against miliary and meningeal forms of TB, with a protective 
efficacy of approximately 60-80%. However, the efficacy of BCG vaccination against 
pulmonary forms of TB varies geographically. [15] Of the children in this study, 56% 
were vaccinated with BCG and 7% were not, with no information available about the 
other 37%. Studies in Mexico [10] and China [16] showed that 93% and 76%, 
respectively, of children with pulmonary TB were vaccinated. Vaccination coverage is 
higher in countries with a high prevalence of TB (e.g. China and Mexico) than in 
countries with intermediate or low prevalence of TB (e.g. Portugal). [15] 
  
The mean time to diagnosis was approximately 83 days, similar to findings in 
Mexico (5 to 150 days)
 
[10] and Vila Nova de Gaia (37 ± 47 days) [17]. TB was 
detected by passive screening in 59% was of our study subjects, similar to findings in 
Madrid (59%)[18] and in Texas (79%). [19] 
  
We found that almost half of our study subjects (47%) were not assessed by 
bacteriological methods. The percentage evaluated by bacterial culture (43%) was 
similar to that in Europe between 2000 and 2009 (42.3%). [1]
 
Diagnosis was confirmed 
by culture in 26% of the children in our study, higher than the rate in Europe in 2009 
(19.2%), [1]
 
but similar to the national percentage in Portugal between 2000 and 2009 
(27.6%).[7] Moreover, 63.5% of the children evaluated microbacteriologically had a 
probable or confirmed diagnosis, compared with 34% in the entire sample. This finding 
indicates the importance of an accurate diagnosis, in particular by utilizing 
microbacteriological methods to assess all children with suspected TB.  
The majority of children studied (85.4%) had mild forms of TB, comparable to a 
European study in which 53.4% of children had pulmonary TB, one form of mild TB. 
[1] In contrast, a study from China reported that 54% of the children studied had 
disseminated forms of TB with extension to organs other than the lungs, [16] compared 
with the 13.5% rate of disseminated TB in this study. The study from China found 
statistically significant differences in several variables between patients with mild and 
severe forms of TB (disseminated or meningeal). Lower age, absence of BCG 
vaccination and shorter time to diagnosis were associated with a greater likelihood of 
more severe forms of TB, and residence was also associated with TB severity. [16] In 
contrast, we were unable to identify any factors associated with disease severity in 
Portuguese children. 
TB in children is an indicator of disease transmission within the community. We found 
that these children are concentrated in large urban centres, where the incidence of TB is 
greater. Early detection and diagnostic confirmation of disease are necessary. We were 
unable to identify predictors of severe forms of disease.  
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Table 1-Absolute (Abs) and relative (Rel) frequency (Freq) for each discrete 
variable and distinction of proportions between children with severe Tuberculosis 
(TB) and mild Tuberculosis 
 
  
Variables Value Abs Freq Range Rel Freq Range Severe TB Mild        TB 
Pearson’s chi-square 
test (p-value) 
Disease 
Mild TB 
Severe TB 
311 
53 
0.854 
0.146 
------ 
------ 
------ 
------ 
----- 
----- 
Detection 
Active screening 
Passive screening 
Unknown 
126 
216 
22 
0.35 
 
0.59 
0.06 
16 
 
31 
6 
110 
 
185 
16 
0.2002 
Inoculation with BCG 
Does not have 
Have 
Unknown 
26 
204 
134 
0.07 
0.56 
0.37 
4 
30 
19 
22 
174 
115 
0.9835 
Comorbidities 
No 
Yes 
351 
13 
0.96 
0.04 
52 
1 
299 
12 
1 
Cities 
Another 
Oporto or Lisbon 
203 
161 
0.558 
0.442 
26 
27 
177 
134 
0.3603 
Country of origin 
Other 
Portugal 
34 
330 
0.09 
0.91 
5 
48 
29 
282 
1 
TST 
Unknown 
Does not have 
Have 
35 
50 
279 
0.09 
0.14 
0.77 
3 
1 
49 
32 
49 
230 
0.09226 
IGRA 
Unknown 
Does not have 
Have 
354 
2 
8 
0.97 
0.01 
0.02 
52 
0 
1 
302 
2 
7 
0.8299 
Microscopy/direct study 
Waits 
Unknown 
Negative 
Positive 
1 
2 
120 
69 
0.003 
0.005 
0.330 
0.190 
0 
0 
23 
10 
1 
2 
97 
59 
0.728 
Specie detection 
Unknown 
No 
Yes 
158 
132 
74 
0.434 
0.363 
0.203 
26 
16 
11 
132 
116 
63 
0.578 
Cultural study 
Waits 
Unknown 
Negative 
Positive 
2 
6 
56 
94 
0.005 
0.016 
0.154 
0.258 
0 
2 
8 
18 
2 
4 
48 
76 
0.5686 
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Dear Editor, 
Worldwide, about 9 million individuals per year are newly 
infected with tuberculosis (TB), with 1 million of them 
being children under 15 years of age.
1
 In Europe between 
2000 and 2009, only 42.3% of patients with pediatric TB 
were assessed by culture, and only 39.9% of those tested 
were culture positive.
1
 Indeed, the confirmation rate 
among pediatric cases was 19.2% in Europe in 2009
1
 and 
27.6% in Portugal from 2000 to 2009.
 2
 The variability and 
low specificity of clinical and radiological findings of TB 
in children indicate the need for a high level of suspicion 
in pediatric patients. 
In Portugal, TB is managed in the 67 tuberculosis 
outpatient centers. These centers are responsible for the 
management of all cases of TB and the screening of at-risk 
populations. The cases that are hospitalized are orientated 
to these outpatient centers as soon as they are released 
from hospital. 
All cases of TB are mandatorily notified to the National 
Tuberculosis Surveillance System (SVIG-TB) by the 
clinician. 
This study was designed to identify the criteria leading to 
the empirical start of antibiotic treatment in Portugal, 
without diagnostic confirmation, in children age <6 years. 
This study was based on the implementation of a web-
based survey, through Medquest®, directed to doctors at 
the national level with experience in TB. Professionals’ 
experience with TB and specifically with TB in pediatric 
age was assessed. This survey included 30 multiple choice 
and simple answer questions, with all responses being 
anonymous. 
The investigation was approved by the Ethics Committee 
of the EPIUnit-Institute of Public Health, University of 
Porto, Porto, Portugal. 
The questionnaires were sent to all tuberculosis outpatient 
centers – two of them failed delivery. Of the 65 surveys 
sent, 29 (44.6%) were completed. Of the 29 responders, 20 
(69%) were female. Mean age of the responders was 48.7 
years, and mean clinical experience was 20 years (range, 2 
to 38 years), including an average of 15.5 years of 
experience in TB management and 11.7 years in 
management of TB in children . 
When asked about their criteria to start treatment in 
children under 6 years of age without diagnostic 
confirmation, 72% cited epidemiological context, 62% 
mentioned radiological abnormalities, and 55% cited 
clinical history and the results of immunological tests, 
including tuberculin and gamma-interferon assays.  
Factors associated with epidemiological context cited as 
the most important in the decision to start treatment 
included history of exposure (n = 25, 86%), 
immunodeficiency (n = 17, 59%) and country of origin 
with a high prevalence of TB (n = 16, 55%). Radiological 
criteria included chest radiography, cited by 76% of 
responders, followed by computerized axial tomography 
(33%). The most valuable imaging findings were nodules 
and cavities (96%), adenopathies (41%), pleural effusion 
(41%) and "tree-in-bud" appearance (26%).  
Clinical determinants associated with the decision to start 
treatment included sustained fever (55%), respiratory 
symptoms (41%) and failure to thrive (34%). The average 
time window considered for these symptoms was 36.5 
days (range, 7 days to 3 months). 
Immunological tests considered relevant to the decision to 
treat included tuberculin tests (41%) and interferon 
gamma assays (28%).  
History of exposure to a patient with active disease and the 
presence of clinical and radiological changes associated 
with disease progression were considered especially 
valuable in determining whether to treat.  Although the 
radiological changes perceived as more suggestive of TB 
are not common presentation under 6 years of age for TB, 
all findings are in agreement with proposed criteria for 
early treatment of TB in children under 6 years of age.
 3,4 
One weakness of our study is that we only received 44.6% 
of the questionnaires sent. A more wide study should be 
done, including pediatricians from the hospital.
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and up to around 30 references and six illustrations (figures or tables). We encourage 
authors to follow the CONSORT guidelines for reporting randomised controlled trials. 
Research articles should usually follow the IMRaD structure (Introduction, Methods, 
Results and Discussion).  
 
Surveillance and outbreak reports: Surveillance articles should focus on 
epidemiological trends regarding a specific disease or a group of diseases with data 
from a national or international surveillance system, but they could also be an analysis 
of a surveillance system or a description of a new surveillance system. Longer reports 
on national or international outbreaks should be submitted once the outbreak has been 
fully investigated and focus on new or unexpected aspects and on lessons learnt. The 
length of these articles is up to ca. 3,500 words, with a minimum of 15 and up to around 
30 references and six illustrations (figures or tables). We encourage authors to follow 
the STROBE guidelines that were set up for observational studies i.e. case-control, 
cohort and cross-sectional studies.  
 
Review articles provide a comprehensive state-of-the-art overview of issues of major 
public health importance within the field of communicable disease surveillance, 
prevention or control. They usually are about 4,000 words in length, and contain up to 
80 references and six illustrations (figures or tables). All review articles should explain 
the search strategy and selection criteria, justify the inclusion/exclusion of material and 
state the sources. For systematic reviews, we encourage authors to follow the PRISMA 
guidelines.  
 
Euroroundups should provide an analysis of a specific aspect or function of 
communicable disease surveillance, prevention or control in at least five European 
countries, and present an in-depth comparison of systems and/or data. The average 
length of these articles is 3,500 words with a minimum of 15 and up to around 30 
references and six illustrations (figures or tables).  
 
Perspectives provide an insightful analysis of practices, policies and guidance on 
communicable disease prevention and control, as well as guidance on developments in 
the field of vaccines and immunisation. These articles have an average length of 2,000 
words, and contain up to 20 references and four illustrations (figures or tables).  
Other material 
The following article categories are not peer reviewed. However, we may consult an 
expert for advice on the content of such items.  
 
Editorials are written by experts invited to comment on articles and special topics 
covered by Eurosurveillance and usually have a maximum of two authors. Editorials are 
usually 1,500 words long and contain a maximum of 20 references and four illustrations 
(figures or tables).  
 
Letters to the editor comment on recent Eurosurveillance articles and should be 
submitted within four weeks after the publication of the article in question. They are 
intended to stimulate scientific discussion and are not a format for the publication of 
original data. Their average length is 600 words, with five or fewer references.  
 
Meeting reports should focus on content and contain up to 2,000 words, 10 references 
(including, when possible, links to full reports of conference activities) and no 
illustrations. They should have no more than two authors. Before submitting a meeting 
report, please contact the editorial team.  
 
News are short texts related to current public health events, either authored or 
commissioned by the Eurosurveillance editorial team. Their length is usually 400 
words, with five or fewer references and no illustrations. News do not have more than 
one or two authors.  
How to submit material  To top  
 
All submissions should be sent through the Eurosurveillance online submission system. 
An online author tutorial is available, if you have any difficulties during the submission 
process.  
All submissions should contain the following information:  
 the article category;  
 a declaration that the material is original and has not been submitted elsewhere; 
 a declaration that all authors have seen and approved the final manuscript; 
 a declaration that the corresponding author, on behalf of all co-authors, has read 
and agreed to the terms of the Eurosurveillance data protection notice; 
 a declaration that informed consent has been obtained from persons whose 
details are described in articles (or from the persons’ guardians) that this 
information may be published; 
 a statement on funding and potential competing interests of the authors; 
 where appropriate, information on approval of the work by an ethics committee; 
 proof of permission to use figures or tables that are adapted or reproduced from 
other publications. 
The following material should be uploaded as separate files:  
 a covering letter; 
 an anonymised manuscript text in Word format (pdf files cannot be evaluated) 
including an abstract of appropriate length and a minimum number of eight 
references for rapid communications and 15 for regular articles. All author-
identifiable information – authors’ names, affiliations and contributions as well 
as any acknowledgements – should NOT be included in the document. No 
illustrations (figures or tables) should be included in this document; 
 authors’ names and affiliations (in the format for publication). The first name of 
each author should be given in full (i.e. an initial should not be given). Where a 
collective author is included (e.g. a working group or disease-specific network) 
and if the persons comprising the group are to be included at the end of the 
article, please list each person in this file; 
 authors’ contributions: the contribution of each author to the article should be 
described. This information will be published at the end of the article; 
 all figures in an appropriate format (see details in the section on formatting and 
style),  
 all tables in Word format; 
 a scan of the agreement with authors signed by the corresponding author on 
behalf of all authors.  
File names of uploaded files must not contain any author-identifiable information that 
may lead to identification of the author. 
After all files and information have been uploaded in the submission system, the 
corresponding author is responsible for checking and approving the pdf. Approval of the 
pdf is required for the article to be sent to the editorial office. 
The pdf that the reviewer will receive contains only the manuscript text and any figures 
and tables. For rapid communications, we also give reviewers access to the source files, 
in case they wish to comment directly in the text. For this reason, authors of rapid 
communications must ensure that all personal information in the properties of the 
manuscript text, figures and tables is removed before submission. See instructions on 
how to remove personal information from Microsoft Word or Excel files. 
Ensuring that the appropriate files contain no author-identifying information allows the 
relevant files to be sent to reviewers. If the above conditions regarding anonymity of 
files and file names are not met, the submission will be returned to the authors, for them 
to amend and resubmit. 
Submissions should conform to the uniform requirements for manuscripts submitted to 
biomedical journals as detailed in: Uniform requirements for manuscripts submitted to 
biomedical journals. International Committee of Medical Journal Editors. Med Educ. 
1999; 33(1):66-78 (http://www.icmje.org/index.html)  
Supplementary material  To top  
 
Eurosurveillance does not publish supplementary material. All necessary information 
should be integrated in the article, while observing the word limit. In exceptional cases, 
where strong reasons preclude publication of certain information as part of the article, 
the authors have the option to make such material available on an independent website 
and to provide a link to this website in the article. Such material is not edited by 
Eurosurveillance and Eurosurveillance is not responsible for the content. 
Formatting and style  To top  
 
Articles should be written in clear, appropriate and scientific language that is free of 
jargon. Avoid abbreviations when possible and define them when you first use them. 
Please use United Kingdom English spelling.  
 
Titles should be interesting, informative, accurate and as short as possible. They should 
contain the place/country and the time period covered in the paper.  
 
Keywords: A maximum of eight keywords suitable for indexing should be provided. 
Please select from the list provided and add others if needed. Separate the keywords by 
a semi-colon (;).  
 
Abstracts of regular articles should stay within the limit of 150 to 200 words, those of 
rapid communications should not exceed 75 words. Abstracts in Eurosurveillance do 
not contain subheadings.  
 
Main text: An introduction should put the topic into perspective using up-to-date 
references, and clearly state the objective of the work and its relevance. The relevant 
methods should be presented at an appropriate level of detail; molecular diagnostic 
techniques that are published or standard, for example, can be named and referenced 
and do not need to be described in detail. It is important to make it clear at all times 
which results are the work of the authors, presented as part of the article, and which are 
already known and given as background or for comparison. If tables and figures are 
provided, the text should shortly describe and summarise the content, but not 
unnecessarily repeat the information; the reader should be able to understand text and 
illustrations independently of each other. The European and international relevance 
should be discussed with relevant references, and where appropriate, lessons learnt and 
recommendations for the future should be presented.  
Tables and figures 
Tables and figures are inserted after the paragraph in which they are mentioned.  
Any references given in them are numbered after the citations in the text, i.e. the 
numbering does not take into account the position of the table or figure in the text.  
Figure/table titles should not contain abbreviations and be as short as possible and 
mention the disease, place and date as well as number of cases/samples shown, so that it 
can be clearly understood what is shown. Further information needed to understand the 
figure or table is presented in the footnote under the illustration, together with 
explanations of all abbreviations and information on the source of the data. Footnotes 
added to specific entries in the table or figure are numbered as superscript a, b, c, etc. in 
order of appearance. The reader should be able to understand an illustration without 
referring to explanations in the text.  
 
Tables and figures that have already been published can only be accepted under specific 
circumstances. In such cases the authors are required to obtain permission from the 
copyright holder to reproduce the illustration in question. Copyright also needs to be 
observed, for example, for maps used as a background for entering data.  
 
Tables should be sent in Word format. They must be uploaded as separate files.  
 
All figures should be uploaded as separate, editable files. Graphs should be provided in 
Excel format. If that is not possible, graphs, as well as phylogenetic trees etc, have to be 
submitted as vector files such as .pdf, .eps, .wmf, .emf, .svg . could be given. All the 
programmes used to create graphs should be able to export a file in at least one of these 
formats. Not all pdfs are vector files: Illustrations should be exported as a pdf directly 
from the programme in which they were created, rather than exporting the illustration in 
another format and then subsequently saving as a pdf.  
Pictures of illustrations simply copied into the above formats cannot be used because 
they cannot be edited. We need the illustration to be linked to the original data. Bitmap 
files (.jpg, .bmp, .gif, etc) are not acceptable. Maps should be provided as vector files 
(.pdf, .eps, .wmf, .emf, .svg). Preferably the maps should not include bitmap elements 
(i.e. map as a picture in the background). Only photographs should be given as high-
resolution bitmap files (.jpg, .tif, etc.). They should be provided as stand-alone original 
files, and not included in Word or PowerPoint documents.  
References 
Citations are numbered in the order of appearance in the text. Reference numbers are 
placed in square brackets [1] in the text. References cited in a table or figure legend 
should be numbered after the citations in the text.  
 
Papers that are accepted for publication can be cited as forthcoming. Papers not yet 
accepted for publication cannot be cited. The source of such information can be 
indicated in parentheses in the text, either as data not shown, if the information comes 
from one of the authors, or as personal communication, if the information comes from 
someone else. Personal communications must include the name of the person and the 
date the communication took place.  
 
References should be formatted according to the uniform requirements for manuscripts 
submitted to biomedical journals’(Vancouver style). Do not use italics, bold or 
underlining.  
#. Author of article AA, Author of article BB, Author of article CC. Title of article. 
Abbreviated Title of Journal. Year;vol(issue):page number(s).  
 
For example:  
1. Geck MJ, Yoo S, Wang JC. Assessment of cervical ligamentous injury in trauma 
patients using MRI. J Spinal Disord. 2001;14(5):371-7.  
 
If there are more than six authors, list the first six authors followed by et al. For 
example:  
1. Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, et al. 
Regulation of interstitial excitatory amino acid concentrations after cortical contusion 
injury. Brain Res. 2002;935(1-2):40-6.  
 
More samples of reference formats can be seen at: 
http://www.nlm.nih.gov/bsd/uniform_requirements.html  
Authors and acknowledgements 
All listed authors should have made substantive intellectual contributions to the article, 
be aware of its submission to Eurosurveillance and able to account for its content. The 
contribution of each author to the article must be stated: this information will be shown 
at the end of the published article.  
We do not limit the number of authors, but for the rapid communications it may be 
more appropriate to list the names of people who have not contributed directly to the 
production of the article in the acknowledgements. You may acknowledge anyone who 
has helped you with any aspect of the report, but it is always the corresponding author’s 
responsibility to obtain permission from anyone being acknowledged. 
Please include complete information about each author (full name, affiliation and the 
name of the institution, city and country in which the work was done). Clearly identify 
and provide telephone number and email address for the corresponding author.  
In our submission system, authors can also include an ORCID (Open Researcher and 
Contributor ID), if they have one. We encourage authors to use this system. 
It is possible to provide a collective name as an author (working group, disease-specific 
network, etc.). The members of such a group can be listed at the end of the article and 
will appear in PubMed/MEDLINE indexation. In the online submission system, the 
corresponding author will be asked whether there is a collective author and for any 
names of members of the group or network to be listed.  
A statement on funding for the work described in the manuscript should be included. 
GISAID sequences 
Although the database of the Global Initiative on Sharing All Influenza Data (GISAID) 
is publicly accessible, it is not open access, and attention should be paid to correct 
attribution of the data used. You should acknowledge the authors, originating and 
submitting laboratories of the sequences from GISAID’s EpiFlu™ Database on which 
the research is based, and to refer to the GISAID website (www.gisaid.org). In addition 
to an appropriate acknowledgement, we recommend including a table in the Methods 
section, listing all sequences with the respective background information, unless there is 
an unmanageable number of them. Examples of how to do this can be found here: 
Article 1, Article 2  
Secondary publication  To top  
 
Eurosurveillance allows authors to submit material that has previously been published 
in a language other than English, if dissemination in English would be beneficial from a 
scientific or public health perspective to a wider readership that cannot read the primary 
publication or has limited access to it. Such publication will mainly be considered for 
short articles on topics that have been previously covered in the bulletins of the national 
surveillance institutes. Eurosurveillance aims to add value to these publications, usually 
by widening the discussion to include other European countries, and including 
additional references. Longer articles are usually not accepted for secondary 
publication. 
It should be clear from the submission that it is secondary publication, and permission 
from the editors of the primary publication must be sought and documented in advance. 
If published, the primary publication should be clearly acknowledged with a reference 
and, where possible, web link to the original material. 
Prospective authors should follow the guidelines in the section III.D.3. of the 
International Committee of Medical Journal Editors' uniform requirements for 
manuscripts submitted to biomedical journals 
(http://www.icmje.org/publishing_4overlap.html)  
Secondary publications are subject to the normal Eurosurveillance review process. 
Evaluation and peer review  To top  
 
Upon submission, the articles are screened by the editorial team and scheduled for 
discussion in the next editorial meeting. Papers received without the necessary 
accompanying material such as signed agreement with authors, conflict of interest 
declaration, manuscript text, abstract and figures in the correct length and format, etc. 
are not considered as submissions and will not be evaluated. 
Manuscripts that pass the first evaluation will be sent for peer review to at least two (for 
rapid communications and e-alerts at least one) independent experts in the field. While 
we try to avoid delays, this part of the process relies on the availability and cooperation 
of the referees and can take considerable time. The reviewer is always a person working 
outside the team or the department of the authors, and is usually from a different 
institute and/or country. We follow a policy of double-blind peer review where both the 
authors’ and the reviewers’ identities are kept confidential.  
In the online submission system, authors can track the status of their submission. If they 
wish to contact the editorial office about their manuscript at any point, this should be 
done by sending an ad hoc email through the submission system (via ‘Action links’).  
Upon receipt of the reviews, the article is evaluated in detail by the editorial team taking 
into account the reviewers' comments and recommendations and is scheduled for the 
next available editorial meeting where a decision will be made whether to proceed with 
the manuscript or to reject it. If the reviewers' opinions are conflicting, the article may 
be sent for a further review.  
If the decision is made to proceed with the manuscript, the reviewers’ comments and 
suggestions are sent to the authors as guidelines for the preparation of a revised draft. 
On rare occasions, we may amend the reviewer’s comments before they are sent to the 
authors, to take into account particular sensitivities or remove passages that are clearly 
intended as recommendations not for the authors but for the editor. When at least two 
reviews are obtained (for all regular articles and for some rapid communications), the 
anonymised comments for the authors will be shared with the other reviewer(s) of the 
manuscript. The editorial decision will also be passed on to the reviewers.  
The invitation to submit a revised manuscript does not imply that the manuscript will 
eventually be accepted for publication. Together with the revised manuscript, the 
authors are required to return a detailed, point-by-point response to the reviewers' 
comments. The editorial team may decide to consult the original referees once more to 
judge whether their concerns have been addressed satisfactorily.  
The revised manuscript is scheduled for final evaluation and editing. Our papers are 
rigorously edited for content and style, and the authors may need to provide further 
information, corrections and clarifications at this stage. Because the editing process 
itself can bring up points that have gone unnoticed before, we do not formally accept a 
manuscript before editing is complete. 
Once the editor and corresponding author have agreed on the final version of the 
manuscript, a final copy is sent to the author for approval and the paper is published in 
one of the next available issues, usually within two weeks from finalisation of the text. 
This may be longer if the article is published as part of a special thematic issue or in the 
context of a particular event.  
Rapid communications and e-alerts follow the same steps but are processed with 
priority to ensure timely dissemination of important public health information. 
Some articles are processed by an editorial board member who is not working at ECDC. 
To avoid potential conflicts of interest, regular articles authored by our colleagues at 
ECDC are processed, whenever possible, by an editorial board member who is not 
working at ECDC, whenever possible. This includes initial evaluation, selection of peer 
reviewers, evaluation of the reviewers’ comments and evaluation of the revisions. After 
that, the editorial team in Stockholm are responsible for the editing. 
Corrections/errata  To top  
 
The editorial team should be informed immediately of any errata or corrections to be 
made. Such changes are made immediately in the original article as well as the pdf, 
together with an editorial note explaining the nature and date of the change.  
Corrections and errata are usually published in the first issue of every month.  
Contacting the editorial team  To top  
 
If you have any questions about Eurosurveillance, please contact our editorial team at 
eurosurveillance@ecdc.europa.eu  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Revista Portuguesa de Pneumonologia 
Instructions for authors 
The Portuguese Journal of Pulmonology will consider for 
publication papers, (original articles or revisions, case 
reports, letters to the editor, commentaries etc) that are 
related directly or indirectly with the Respiratory System. 
The opinions expressed are exclusively the responsibility 
of the authors. Articles published will remain the property 
of the Portuguese Journal of Pulmonology, not to be 
reproduced, wholly or partially, without the permission of 
the editor. 
All manuscripts are evaluated by members of the editorial 
board of the journal and acceptance for publication of articles 
or original research, clinical reports or series of case studies 
which are accepted, are subject to a technical assessment by 
the editorial board. In this evaluation process articles may be: 
a) Accepted without alteration 
b) Accepted after suggested modifi cations have been agreed 
by the authors 
c) Refused 
Only manuscripts containing original material which has not 
yet been published, wholly or partially (including tables 
and fi gures), and which have not been submitted to be 
published elsewhere, will be considered for publication. 
Before submitting manuscripts, authors must obtain all 
necessary authorizations for the publication of the submitted 
material. 
Presentation of manuscripts − Texts should be written 
in English. Manuscripts submitted to the journal should 
include the manuscript organized according to the guidelines 
presented under the Instructions to Authors. Manuscripts 
should be prepared in Microsoft Word processor or compatible 
software containing a Title Page, Abstract, Introduction, 
Methods, Results, Discussion, Reference List, Figure 
Legends, Tables numbered in Arabic numbers along with 
the corresponding title. Online submission is available at 
http://ees.elsevier. com/rpp 
Please note that the reproduction of images, pictures 
or graphics from other publications must have prior 
authorization from the respective authors to comply with 
norms of the regulations governing the rights of authors. They 
should be included in the references, by author, as original 
articles, revisions, letters to the editor or other. All original 
articles after acceptance will also be published in Portuguese; 
the authors will be responsible for the translation of the 
respective articles, to be reviewed by the Editorial Board. 
Structure − The usual convention for structure should be 
employed, in which a new page is used for each separate 
section of the work, in the following order: 
a) The fi rst page: Title of work and name/s or author/s 
with respective academic and/or professional titles, 
department where the study was carried out, respective 
contact addresses and e-mails. Where the number of 
authors exceeds six, this must be justifi ed. 
b) The next page/s: 
— An abstract in English which must not exceed 250 words 
for original works and 150 for case reports. 
— Key words (3 to 10), which provide the index for the 
article, according to the terminology of the Medical 
Index “Medical Subject Headings”. 
c) The text, in the case or original articles, will generally be: 
Introduction, Material and Methods, Results, Discussion 
and Conclusions. 
d) Acknowledgements 
e) References 
f) Tables and Figures 
Authorship − According to “Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals”, authorship 
implies a substantial contribution to the manuscript. It is 
therefore necessary in the covering letter to specify the 
contribution made by each author to the work. 
Example: António Costa conceived this study and supervised 
all aspects of its implementation. José Costa collaborated in 
the inception of the study and carried out the analysis of the 
data. Manuel Costa collected the data and collaborated in the 
analysis. All the authors contributed to the interpretation of 
the results and the proof reading of the manuscript. 
Presentation of work − The whole manuscript, including 
references, tables and fi gures, should be formatted in 
double-spacing, 12 point letter size, and justifi ed on the left. 
All pages must be numbered, including the title page. Margins 
in the whole manuscript must be 2.5 cm margins. Page breaks 
must be inserted between each section. In manuscripts signed 
by more than 6 authors (3 authors in the case of letters to 
the editor), there has to be an explicit explanation for such 
an extensive authorship. 
TYPES OF ARTICLES 
Articles on original research: The text must not exceed 2000 
words, excluding references and tables, and be organized 
into introduction, methods, results and discussion, with a 
maximum of 4 tables and/or fi gures. In the materials and 
methods there must be a complete and appropriate reference 
to the statistical methods used and the results should be quite 
suffi ciently explicit. 
Review articles: The Portuguese Journal of Pulmonology 
publishes primarily review articles which have been requested 
by the editors. However, unsolicited articles submitted will be 
considered, particularly systematic reviews (meta-analysis). 
The text must not exceed 5000 words, excluding references 
and tables, with a maximum of 5 tables and/or fi gures in 
total. The reviews must be organized systematically in introduction, 
methods, results and discussion. 
Short publications: Preliminary results or new fi ndings could 
lead to short publications. The text should not exceed 1000 
words, excluding references and tables, and be organized 
into introduction, methods, results and discussion, with a 
maximum of 2 tables and/or fi gures in total and up to 10 
references. The short publications should be submitted with 
formal abstracts in Portuguese and English, of not more than 
250 words each. 
Commentaries: Commentaries, essays, critical analyses or 
declarations of a position in relation to topics of interest 
in the area of health, particular the politics of health and 
medical education will be considered. The text must not 
exceed 900 words, excluding references and tables, and 
include a maximum of one table or fi gure. Commentaries do 
not require abstracts; they will normally be at the request of 
the editors. 
Special articles: Where appropriate the editorial board may 
invite one or various authors to write an article on a subject of 
particular formative interest in achieving the priorities of the 
journal and where the subject matter is not being addressed 
by other areas of study (for example postgraduate study). 
Clinical case studies (case reports): The text should not 
exceed 1200 words, excluding references and tables, with 
a maximum of 2 tables and/or fi gures in total. Clinical 
case studies should be submitted with formal abstracts in 
Portuguese and English, of not more than 120 words each. 
Depending on their interest and originality the clinical case 
studies may include a commentary/discussion by one of the 
editors or by an invited reviewer. (Clinical case study with 
discussion) 
Letters to the editor: Two types of letter to the editor are 
considered, clinical notes and correspondence. 
Clinical notes stand for a very objective reporting of results of 
clinical observation or original research for which a detailed 
development is not appropriate. The text should not exceed 
700 words, excluding references and tables, and can include a 
maximum of one table or fi gure and up to 7 references. 
Correspondence refers to a succinct commentaries on 
articles published in the Portuguese Journal of Pulmonology, 
preferably within the previous 6 months. In this case, the 
text should not exceed 500 words, excluding references and 
tables, and can include a maximum of one table or fi gure and 
up to 5 references. 
Letters to the editor should not include abstracts. 
Bibliography − Bibliographical references must be numbered 
in consecutive order from the fi rst citation in the text. The 
text must be identifi ed by Arabic numerals. The references 
must contain, in the case of reviews, the name of the fi rst 
author (surname and given name), followed by the other 
authors, the title of the article, the name of the publication 
and the identifi cation (year, volume and page). 
A detailed description of the format of different types of 
references may be found in “Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals”, of which the 
following is an example. 
Tables and fi gures – Tables and fi gures must be presented on 
separate pages, of high quality, suitable for reproduction, 
in the order they are discussed in the text. They should be 
accompanied by their respective titles in a way that they 
can be understood and interpreted without recourse to the 
written text. All graphs must be presented in the form of 
photographs of the respective original. Original photographs 
should not be sent nor should illustrations or other materials 
like X-ray fi lms. 
Figures created on computer or in electronic format after 
digitalization should be enclosed in the manuscript folder. 
The costs of publication of pictures in colour will be covered 
by the authors. When manuscripts are accepted pictures will 
be requested in the most appropriate format for publication 
in the journal. 
Annexes − Very extensive material for publication with 
the manuscript, particularly extensive tables or tools for 
data retrieval, may in certain cases, after consideration, be 
placed on the Internet to be consulted by those interested 
(Supplementary Material). 
Ethical considerations and informed consent − The authors 
must ensure that all research involving human beings has been 
approved by the ethical commissions within the institutions 
where the research was carried out, conforming to the Helsinki 
Declaration of the Association of World Medicine (www.wma. 
net). In the methods section of the manuscript this approval 
must be included as well whether, where applicable, informed 
consent has been obtained. In the submission of clinical 
reports it is obligatory to include the consent of the patients. 
Confl ict of Interest – The authors of any manuscript submitted 
must disclose at the time of submission whether there exists 
a confl ict of interest otherwise make a declaration that there 
is none. This information will be kept confi dential during the 
consideration of the manuscripts by the external assessors 
and would not infl uence the editorial decision but will be 
published should the article be accepted. 
Informed Consent − A statement on obtaining the patient 
informed consents. If photographs or patient data are 
reproduced in the article (including names, initials, or 
hospital numbers of the patients or judicial proceedings 
numbers), these must not be able to identify the subject. 
In all cases, the authors must have obtained the written 
informed consent from the patient (or legal representative, or 
parent or guardian if the patients are minors), that authorises 
its publication, reproduction and circulation on paper support 
and on the internet in Portuguese Journal of Pulmonology. 
Modifi cations and revisions – In the case of articles being 
accepted subject to modifi cations, changes must be made by 
the author within fi fteen days (for “minor” modifi cations) or 
2 months (for “major” modifi cations). The proof reading will 
be the responsibility of the Editorial Board unless the authors 
indicate otherwise. In the latter case the changes must be 
made within the time limit set by the Editorial Board, to 
comply with. 
SUBMISSION OF MANUSCRIPTS 
Manuscripts submitted to the Portuguese Journal of 
Pulmonology must conform to the recommendations indicated 
above and must be accompanied by a covering letter. The 
Editorial Board will acknowledge receipt of manuscripts, 
supplying information as to the orientation category given 
to the relevant article. Whenever there are editorial 
recommendations to changes to the manuscripts sent, the 
authors should supply a new version with an explanation of 
changes made. Correspondence between the authors and the 
journal should be conducted electronically, by the Elsevier 
Editorial System (http://ees. elsevier.com/rpp). 
 
